Results 11 to 20 of about 34,491 (205)

Omeprazole and adenocarcinoma in the stomach of rats submitted to duodenogastric reflux. Is there a protective effect? [PDF]

open access: yesActa Cirúrgica Brasileira, 2020
Purpose: To investigate the role of omeprazole and nitrites on the gastric mucosa of rats submitted to specific techniques to induce duodenogastric reflux.
Rosângela Lucinda Rocha Monteiro   +4 more
doaj   +1 more source

Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics [PDF]

open access: yes, 2022
INTRODUCTION: The prevalence of obesity is increasing globally. The principal aim was to evaluate whether gastric bypass surgery modifies the bioavailability and pharmacokinetic (PK) parameters of omeprazole.
Rubio, Miguel A.   +16 more
core   +1 more source

Omeprazole treatment manifests anxiolytic effects in a cysteamine hydrochloride induced mouse model of gastrointestinal disorder

open access: yesHeliyon, 2022
Omeprazole, a proton pump inhibitor (PPI), has widely been used to treat various gastrointestinal (GI) disorders. Notably, many clinical symptoms of GI disorders have been known to be associated with anxiety.
Harini Sri Rethinavel   +5 more
doaj   +1 more source

Reno-protective Role of Ginseng in Counteracting the Long-term Omeprazole Induced Adverse Effects in Albino Rats via Modulation of Inflammation, Apoptosis and Fibrosis [PDF]

open access: yesMinia Journal of Medical Research, 2023
Background: Omeprazole has long-term use adverse effects even though is commonly used. Aim: Evaluation of the possible renal protective effect of ginseng against the long-term omeprazole-induced adverse effects.
Dina Maher   +3 more
doaj   +1 more source

Effect of Laparoscopic Sleeve Gastrectomy on the Pharmacokinetics of Oral Omeprazole Using a Population Approach

open access: yesPharmaceutics, 2022
Omeprazole is commonly prescribed to obese patients and patients after laparoscopic sleeve gastrectomy (LSG). The pharmacokinetics of oral omeprazole after LSG are still unknown. Therefore, the aim of this study was to investigate the pharmacokinetics of
Kaifeng Chen   +8 more
doaj   +1 more source

Omeprazole physiological based pharmacokinetics model (PBPK)

open access: yes, 2021
This repository provides the omeprazole physiological based pharmacokinetics/pharmacodynamics model (PBPK/PD). If you have any questions or problems please open an issue FundingMatthias König is supported by the Federal Ministry of Education and Research
Balci, Sükrü, König, Matthias
core   +1 more source

Omeprazole Prevents Colistin-Induced Nephrotoxicity in Rats: Emphasis on Oxidative Stress, Inflammation, Apoptosis and Colistin Accumulation in Kidneys

open access: yesPharmaceuticals, 2022
The clinical value of colistin, a polymyxin antibiotic, is limited by its nephrotoxicity. Omeprazole is a commonly prescribed proton pump inhibitor.
Mohammed Z. Nasrullah   +6 more
doaj   +1 more source

Omeprazole-induced galactorrhea in kidney transplant patients—a case report

open access: yesJournal of Medical Case Reports, 2022
Background Omeprazole belongs to the pharmacological classifications of proton pump inhibitors and is a widely used medicine. All proton pump inhibitors have a common mechanism of action and are prodrugs that require activation in an acidic environment ...
Choki Dorji   +2 more
doaj   +1 more source

Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection [PDF]

open access: yes, 1998
In this randomized, multicenter trial, we evaluated the effectiveness and side effect profile of a modified omeprazole-based triple therapy to cure Helicobacter pylori infection.
Miehlke, Stephan   +11 more
core   +1 more source

Phase 1 Study of Safety and PK With A Combination of Omeprazole and Trimetazidine for Fatty Acid Oxidation Inhibition in Patients With Advanced Solid Tumors. [PDF]

open access: yesClin Transl Sci
ABSTRACT Fatty acid oxidation (FAO) is a metabolic vulnerability in cancer cells, making pharmacologic FAO inhibition a promising therapeutic strategy. This Phase I, open‐label, 3 + 3 dose‐escalation study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of two oral FAO inhibitors—omeprazole (KN510), a carnitine ...
Choi W   +11 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy